What is BioNexus Gene Lab Corp. (BGLC)?

BioNexus Gene Lab Corp. (BGLC) is a stock in the Industrials sector, Industrial - Distribution industry. View full analysis on Stocks360.

What is the current price of BGLC?

The current price of BGLC is $1.06. Prices are updated in real time on Stocks360.

What is BGLC's price-to-earnings (PE) ratio?

BGLC's trailing twelve-month PE ratio is -0.84, based on current price and earnings per share data available on Stocks360.

What is BGLC's market capitalization?

BGLC's market capitalization is $2,569,121.00, placing it in the small-cap tier.

BioNexus Gene Lab Corp. (BGLC)

Stock analysis · NASDAQ · Industrials · Industrial - Distribution

$1.06

Market Cap

$2.57M

PE (TTM)

-0.84

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.20

Day Range

$1.03 – $1.13

52-wk Range

$1.06 – $5.67

Avg Volume

N/A

Volume

4.00K

BioNexus Gene Lab Corp. (BGLC) is a publicly traded company in the Industrials sector. Latest price: $1.06. Market cap $2.57M. Trailing PE -0.84. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $5.12 2026-10-28 · $1.06 (-79.30%)

Proprietary Signals

Signal snapshot temporarily unavailable.

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.84×
P/S (TTM)	0.82×
P/B	0.33×
P/FCF (TTM)	-2.95×
EV / EBITDA	-0.64×
EV / Sales	0.49×
Earnings Yield	-100.23%
Free Cash Flow Yield	-33.88%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.54M
Revenue (TTM)	$3.13M
Net Income (TTM)	-$2.58M
Free Cash Flow (TTM)	-$864.06K
Net Debt	-$1.03M
Working Capital	$4.13M
Gross Margin	11.64%
Operating Margin	-82.78%
Net Margin	-82.36%
Return on Equity	-32.91%
Return on Invested Capital	-32.45%